Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor

A secondary analysis of the DEEP Trial

Garrett K. Lam, Moana Hopoate-Sitake, Charles Adair, Vardaman M. Buckalew, Donna D. Johnson, David F. Lewis, Christopher J. Robinson, George R. Saade, Steven W. Graves

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Endogenous digitalis-like factors (EDLFs) are elevated in women with preeclampsia, and the use of an anti-digoxin antibody Fab (DIF) in women with preeclampsia who were remote from term reduced maternal blood pressure and preserved renal function. The objective was to determine whether DIF treatment in women with severe preeclampsia in association with positive EDLFs in maternal serum improves maternal-perinatal outcomes. Study Design: This was a planned secondary analysis from a randomized, placebo-controlled, double-blind study of DIF in women with severe preeclampsia with positive EDLF status that was managed expectantly between 23 weeks 5 days and 34 weeks' gestation (19 women received placebo, and 17 women received DIF). Primary outcome variables were a change in creatinine clearance and the use of antihypertensives. Secondary outcomes were maternal and perinatal complications. Results: Women with positive EDLFs who received DIF had an attenuated decline in creatinine clearance from baseline compared with placebo (-4.5 ± 12.9 vs -53.2 ± 12.6 mL/min; P =.005). In this same group, the use of antihypertensives (the other primary outcome) was lower but not significantly so (41% vs 63%; P =.12). However, women who were treated with DIF had a lower rate of pulmonary edema (1/17 vs 6/19 women; P =.035) and lower rates of neonatal intraventricular hemorrhage (DIF: 0/17 women vs placebo: 5/19 women; P =.015). Conclusion: In women with severe preeclampsia who were remote from term who were EDLF positive, the use of DIF was associated with improved maternal and neonatal outcome. These findings suggest the need for a large multicenter trial that would evaluate the benefits of DIF in the treatment of women with severe preeclampsia who are remote from term and with positive EDLF status.

Original languageEnglish (US)
Pages (from-to)119.e1-119.e6
JournalAmerican Journal of Obstetrics and Gynecology
Volume209
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Immunoglobulin Fragments
Digoxin
Pre-Eclampsia
Antigens
Antibodies
Mothers
Therapeutics
Placebos
digoxin-like factors
Antihypertensive Agents
Creatinine
Pulmonary Edema
Double-Blind Method
Multicenter Studies
Anti-Idiotypic Antibodies

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor : A secondary analysis of the DEEP Trial. / Lam, Garrett K.; Hopoate-Sitake, Moana; Adair, Charles; Buckalew, Vardaman M.; Johnson, Donna D.; Lewis, David F.; Robinson, Christopher J.; Saade, George R.; Graves, Steven W.

In: American Journal of Obstetrics and Gynecology, Vol. 209, No. 2, 01.01.2013, p. 119.e1-119.e6.

Research output: Contribution to journalArticle

Lam, Garrett K. ; Hopoate-Sitake, Moana ; Adair, Charles ; Buckalew, Vardaman M. ; Johnson, Donna D. ; Lewis, David F. ; Robinson, Christopher J. ; Saade, George R. ; Graves, Steven W. / Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor : A secondary analysis of the DEEP Trial. In: American Journal of Obstetrics and Gynecology. 2013 ; Vol. 209, No. 2. pp. 119.e1-119.e6.
@article{a30e87b29c504ccca3b5a32a45404c36,
title = "Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: A secondary analysis of the DEEP Trial",
abstract = "Objective: Endogenous digitalis-like factors (EDLFs) are elevated in women with preeclampsia, and the use of an anti-digoxin antibody Fab (DIF) in women with preeclampsia who were remote from term reduced maternal blood pressure and preserved renal function. The objective was to determine whether DIF treatment in women with severe preeclampsia in association with positive EDLFs in maternal serum improves maternal-perinatal outcomes. Study Design: This was a planned secondary analysis from a randomized, placebo-controlled, double-blind study of DIF in women with severe preeclampsia with positive EDLF status that was managed expectantly between 23 weeks 5 days and 34 weeks' gestation (19 women received placebo, and 17 women received DIF). Primary outcome variables were a change in creatinine clearance and the use of antihypertensives. Secondary outcomes were maternal and perinatal complications. Results: Women with positive EDLFs who received DIF had an attenuated decline in creatinine clearance from baseline compared with placebo (-4.5 ± 12.9 vs -53.2 ± 12.6 mL/min; P =.005). In this same group, the use of antihypertensives (the other primary outcome) was lower but not significantly so (41{\%} vs 63{\%}; P =.12). However, women who were treated with DIF had a lower rate of pulmonary edema (1/17 vs 6/19 women; P =.035) and lower rates of neonatal intraventricular hemorrhage (DIF: 0/17 women vs placebo: 5/19 women; P =.015). Conclusion: In women with severe preeclampsia who were remote from term who were EDLF positive, the use of DIF was associated with improved maternal and neonatal outcome. These findings suggest the need for a large multicenter trial that would evaluate the benefits of DIF in the treatment of women with severe preeclampsia who are remote from term and with positive EDLF status.",
author = "Lam, {Garrett K.} and Moana Hopoate-Sitake and Charles Adair and Buckalew, {Vardaman M.} and Johnson, {Donna D.} and Lewis, {David F.} and Robinson, {Christopher J.} and Saade, {George R.} and Graves, {Steven W.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.ajog.2013.04.010",
language = "English (US)",
volume = "209",
pages = "119.e1--119.e6",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor

T2 - A secondary analysis of the DEEP Trial

AU - Lam, Garrett K.

AU - Hopoate-Sitake, Moana

AU - Adair, Charles

AU - Buckalew, Vardaman M.

AU - Johnson, Donna D.

AU - Lewis, David F.

AU - Robinson, Christopher J.

AU - Saade, George R.

AU - Graves, Steven W.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: Endogenous digitalis-like factors (EDLFs) are elevated in women with preeclampsia, and the use of an anti-digoxin antibody Fab (DIF) in women with preeclampsia who were remote from term reduced maternal blood pressure and preserved renal function. The objective was to determine whether DIF treatment in women with severe preeclampsia in association with positive EDLFs in maternal serum improves maternal-perinatal outcomes. Study Design: This was a planned secondary analysis from a randomized, placebo-controlled, double-blind study of DIF in women with severe preeclampsia with positive EDLF status that was managed expectantly between 23 weeks 5 days and 34 weeks' gestation (19 women received placebo, and 17 women received DIF). Primary outcome variables were a change in creatinine clearance and the use of antihypertensives. Secondary outcomes were maternal and perinatal complications. Results: Women with positive EDLFs who received DIF had an attenuated decline in creatinine clearance from baseline compared with placebo (-4.5 ± 12.9 vs -53.2 ± 12.6 mL/min; P =.005). In this same group, the use of antihypertensives (the other primary outcome) was lower but not significantly so (41% vs 63%; P =.12). However, women who were treated with DIF had a lower rate of pulmonary edema (1/17 vs 6/19 women; P =.035) and lower rates of neonatal intraventricular hemorrhage (DIF: 0/17 women vs placebo: 5/19 women; P =.015). Conclusion: In women with severe preeclampsia who were remote from term who were EDLF positive, the use of DIF was associated with improved maternal and neonatal outcome. These findings suggest the need for a large multicenter trial that would evaluate the benefits of DIF in the treatment of women with severe preeclampsia who are remote from term and with positive EDLF status.

AB - Objective: Endogenous digitalis-like factors (EDLFs) are elevated in women with preeclampsia, and the use of an anti-digoxin antibody Fab (DIF) in women with preeclampsia who were remote from term reduced maternal blood pressure and preserved renal function. The objective was to determine whether DIF treatment in women with severe preeclampsia in association with positive EDLFs in maternal serum improves maternal-perinatal outcomes. Study Design: This was a planned secondary analysis from a randomized, placebo-controlled, double-blind study of DIF in women with severe preeclampsia with positive EDLF status that was managed expectantly between 23 weeks 5 days and 34 weeks' gestation (19 women received placebo, and 17 women received DIF). Primary outcome variables were a change in creatinine clearance and the use of antihypertensives. Secondary outcomes were maternal and perinatal complications. Results: Women with positive EDLFs who received DIF had an attenuated decline in creatinine clearance from baseline compared with placebo (-4.5 ± 12.9 vs -53.2 ± 12.6 mL/min; P =.005). In this same group, the use of antihypertensives (the other primary outcome) was lower but not significantly so (41% vs 63%; P =.12). However, women who were treated with DIF had a lower rate of pulmonary edema (1/17 vs 6/19 women; P =.035) and lower rates of neonatal intraventricular hemorrhage (DIF: 0/17 women vs placebo: 5/19 women; P =.015). Conclusion: In women with severe preeclampsia who were remote from term who were EDLF positive, the use of DIF was associated with improved maternal and neonatal outcome. These findings suggest the need for a large multicenter trial that would evaluate the benefits of DIF in the treatment of women with severe preeclampsia who are remote from term and with positive EDLF status.

UR - http://www.scopus.com/inward/record.url?scp=84880916651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880916651&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2013.04.010

DO - 10.1016/j.ajog.2013.04.010

M3 - Article

VL - 209

SP - 119.e1-119.e6

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -